OptiBiotix Health PLC GoFigure® agreement for Southern Africa (6620M)
18 Septiembre 2019 - 1:00AM
UK Regulatory
TIDMOPTI
RNS Number : 6620M
OptiBiotix Health PLC
18 September 2019
OptiBiotix Health plc
("OptiBiotix" or the "Company")
GoFigure(R) distribution agreement for Southern Africa
OptiBiotix Health plc (AIM: OPTI), a life sciences business
developing compounds to tackle obesity, high
cholesterol, diabetes and skincare, announces it has entered
into a one year exclusive distribution agreement with a South
African partner ("The Partner") to distribute its own label
GoFigure(R) consumer weight management products in South Africa and
neighbouring countries.
The agreement grants The Partner the exclusive rights to import,
market and distribute OptiBiotix's GoFigure(R) range of products
containing its award-winning SlimBiome(R) weight management
technology. This agreement has been signed accompanied by minimum
order quantities to be placed within three and 12 months of signing
to retain exclusivity.
The Partner wishes to remain anonymous until the official launch
date of the GoFigure(R) brand in South Africa has been confirmed.
The Partner has more than 20 years of experience in the
pharmaceutical and health & wellness markets and has
successfully commercialised and promoted a wide range of products
to a broad network within the region, spanning the full supply
chain.
Dr. Fred Narbel, Managing Director of OptiBiotix's prebiotics
division, commented: "We are pleased to announce the signing of
this exclusive distribution deal for the commercialisation of our
GoFigure(R) products in South Africa and neighbouring countries (a
market estimated to be worth ZAR3.8billion in 2016 source:
https://pharmadynamics.co.za/sas-health-supplement-market-booming/).
The agreement is another strategic step to take OptiBiotix's
GoFigure(R) products to international markets which is important as
it builds brand recognition, enhancing brand value and creates a
further demand for SlimBiome(R), the functional ingredient within
GoFigure(R) products. This is an exciting second step in taking
OptiBiotix's own label GoFigure(R) products to international
markets and follows on the announcement of an earlier deal in
Poland (RNS: 22 May 2019)."
This announcement contains inside information for the purposes
of Article 7 of EU Regulation 596/2014.
For further information, please contact:
OptiBiotix Health plc www.optibiotix.com
Stephen O'Hara, Chief Executive Contact via Walbrook
below
Cairn Financial Advisers LLP (NOMAD) Tel: 020 7213 0880
Liam Murray / Jo Turner / Ludovico Lazzaretti
finnCap (Broker) Tel: 020 7220 0500
Geoff Nash / Kate Bannatyne (Corporate Finance)
Camille Gochez (Corporate Broking)
goetzpartners securities Limited Tel: 0203 859 7725
Ulrich Kinzel
Walbrook PR Ltd Mob: 07876 741 001
Anna Dunphy
About OptiBiotix - www.optibiotix.com
OptiBiotix Health plc (AIM: OPTI), which was formed in March
2012, brings science to the development of compounds which modify
the human microbiome - the collective genome of the microbes in the
body - in order to prevent and manage human disease and promote
wellness.
OptiBiotix has an extensive R&D program working with leading
academics in the development of microbial strains, compounds, and
formulations which are used as active ingredients and supplements.
More than twenty international food and healthcare supplement
companies have signed agreements with OptiBiotix to incorporate
their human microbiome modulators into a wide range of food
products and drinks.
OptiBiotix is also developing its own range of consumer
supplements and health products. The Company's current areas of
focus include obesity, cardiovascular health, and diabetes.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
AGRBSGDCDXBBGCR
(END) Dow Jones Newswires
September 18, 2019 02:00 ET (06:00 GMT)
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Optibiotix Health (LSE:OPTI)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024